Anti-inflammatory compounds and uses thereof

Abstract

Compounds of the general formulaare disclosed with activity towards treating diseases related to inflammation, such as cancer, neurodegenerative and cardiovascular diseases. Pharmaceutical compositions and methods of use are also described.

1 - 19 . (canceled) 
     
     
         20 . A pharmaceutically acceptable topical formulation comprising a compound selected from: 
       
         
           
           
               
               
           
         
       
     
     
         21 . The pharmaceutically acceptable topical formulation of  claim 20 , wherein the compound is Phospho-sulindac I. 
     
     
         22 . The pharmaceutically acceptable topical formulation of  claim 20 , wherein the compound is Phospho-sulindac II. 
     
     
         23 . The pharmaceutically acceptable topical formulation of  claim 20 , wherein the formulation further comprises a carrier. 
     
     
         24 . The pharmaceutically acceptable topical formulation of  claim 23 , wherein the carrier is selected from a solvent, cream, lotion, ointment, oil, plaster, liposome, powder, emulsion, microemulsion, and buffered solution. 
     
     
         25 . The pharmaceutically acceptable topical formulation of  claim 24 , wherein the carrier is a solvent. 
     
     
         26 . The pharmaceutically acceptable topical formulation of  claim 25 , wherein the solvent is selected from an alcohol, poly alcohol, and water. 
     
     
         27 . The pharmaceutically acceptable topical formulation of  claim 24 , wherein the carrier is a cream. 
     
     
         28 . The pharmaceutically acceptable topical formulation of  claim 24 , wherein the carrier is an ointment. 
     
     
         29 . The pharmaceutically acceptable topical formulation of  claim 20 , wherein the formulation comprises one or more excipients. 
     
     
         30 . The pharmaceutically acceptable topical formulation of  claim 29 , wherein the one or more excipients are selected from a preservative, antioxidant, moisturizer, emollient, buffering agent, solubilizing agent, penetration agent, skin protectant, surfactant, and propellant. 
     
     
         31 . The pharmaceutically acceptable topical formulation of  claim 30 , wherein the one or more excipients includes a solubilizing agent. 
     
     
         32 . The pharmaceutically acceptable topical formulation of  claim 31 , wherein the solubilizing agent is selected from a quaternary ammonium chloride, cyclodextrin, benzyl benzoate, lecithin, and polysorbate. 
     
     
         33 . The pharmaceutically acceptable topical formulation of  claim 20 , wherein the formulation is in a form selected from an ointment, paste, cream, lotion, gel, powder, solution, spray, inhalant and patch. 
     
     
         34 . The pharmaceutically acceptable topical formulation of  claim 33 , wherein the form is an ointment. 
     
     
         35 . The pharmaceutically acceptable topical formulation of  claim 33 , wherein the form is a cream. 
     
     
         36 . The pharmaceutically acceptable topical formulation of  claim 33 , wherein the form is a solution. 
     
     
         37 . The pharmaceutically acceptable topical formulation of  claim 20 , wherein the formulation is formulated as an ophthalmic formulation, eardrops, or eye drops. 
     
     
         38 . The pharmaceutically acceptable topical formulation of  claim 37 , wherein the formulation is formulated as eye drops.